Opinion
Video
Author(s):
Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.
Asciminib Bests Standard-of-Care TKIs in Ph+ CML
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Desai Details Efforts Exploring Treatment Strategies in CLL Post–BTK Inhibitor Progression
Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma
Vanderbilt Symposium Highlights Recent Data on Novel Agents Under Evaluation in Hematologic Malignancies
Exploiting the Vulnerabilities of High-Grade Serous Ovarian Cancer Through WEE1 Inhibition
Lorlatinib Yields Longest Reported PFS in Advanced NSCLC
Rivoceranib Plus Camrelizumab Maintains Frontline Survival Benefit in Unresectable HCC
Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma